Benzodiazepine use among U.S. adults aged 65 years and older declined before 2020 but remained largely unchanged through 2024. Long-term use persisted in roughly one-third of users, with smaller reductions among adults aged 75 years and older.

The FDA issued a Class II recall for an amphetamine-based ADHD medication after a labeling mix-up resulted in immediate-release capsules being packaged as extended release. The recall affects a single lot totaling 1,392 bottles.

Across 14 health-system specialty pharmacies, pharmacist interventions were associated with an estimated $3.6 million in avoided medication costs over six months. The analysis used a structured attribution method to assess the likelihood that individual interventions altered treatment trajectories.

Medicare’s new GLP-1 Bridge Program expands lower-cost access to certain weight-loss medications for eligible beneficiaries. Concurrent ISMP guidance outlines common medication errors and counseling challenges as more patients initiate GLP-1 therapy.

A post-thyroidectomy patient’s LDL-C rose above 250 mg/dL during recurrent hypothyroidism and improved after euthyroidism returned. The case highlights medication adherence and secondary-cause review before lipid-therapy escalation.

In a 3-year randomized clinical trial, dialectical behavior therapy and schema therapy produced substantial improvements in borderline personality disorder severity. No statistically significant differences were observed between treatments on primary or secondary outcomes.